Free Trial

Boston Common Asset Management LLC Raises Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Hologic logo with Medical background

Boston Common Asset Management LLC increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 19.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 272,320 shares of the medical equipment provider's stock after purchasing an additional 44,756 shares during the quarter. Boston Common Asset Management LLC owned 0.12% of Hologic worth $16,821,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Venturi Wealth Management LLC increased its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Smithfield Trust Co increased its position in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in Hologic during the fourth quarter valued at $49,000. Institutional investors own 94.73% of the company's stock.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the firm's stock in a transaction on Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.88% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Raymond James reiterated an "outperform" rating and issued a $71.00 target price (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Stephens decreased their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Finally, Royal Bank of Canada decreased their price objective on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $77.42.

Get Our Latest Analysis on Hologic

Hologic Stock Performance

NASDAQ:HOLX traded up $0.12 during trading hours on Monday, reaching $62.29. The company had a trading volume of 841,280 shares, compared to its average volume of 2,263,037. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The firm has a market cap of $13.88 billion, a PE ratio of 19.66, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The business's 50 day moving average price is $58.14 and its 200-day moving average price is $65.80. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business's revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $1.03 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

See Also

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Should You Invest $1,000 in Hologic Right Now?

Before you consider Hologic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.

While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Rising Stocks You’ll Want on Your Watchlist
Trillions in Defense Spending—3 Disruptive Stocks Set to Double
The Next Palantir? AI-Defense Stock Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines